Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
for Solid Tumours
4 locations incl. New York
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT07446855·Phase 1, Phase 2·Recruiting